Conduit Secures Patent For Enhanced AZD5904, Unlocking Broader Development In Inflammation And Infertility

Conduit Pharmaceuticals has filed a new composition of matter patent for a novel solid form of AZD5904, a myeloperoxidase (MPO) inhibitor in its clinical pipeline. This newly patented form offers significantly improved solubility, enabling formulations that were previously not viable. The enhanced pharmacokinetics make the drug more suitable for targeting diseases driven by oxidative stress and inflammation, aligning better with patient needs and expanding its clinical potential.

"This new patent application represents a meaningful advance in the life cycle of AZD5904, with composition of matter protection now in place, we have the ability to fully unlock the therapeutic and commercial potential of this compound, including through novel formulation strategies that better suit the underlying disease mechanisms," commented Dr. Andrew Regan, Chief Executive Officer of Conduit Pharmaceuticals.

Initially created by AstraZeneca, AZD5904 proved good target engagement in five Phase 1 trials with negligible safety concerns and was previously limited to development for idiopathic male infertility (IMI). This new patent extends potential intellectual property rights for up to 20 years along the path for wider clinical development and repositioning this asset beyond infertility to other conditions triggered by inflammation, such as multiple sclerosis and COPD. AZD5904 has shown great preclinical efficacy to rescue sperm function in IMI models and shows promise in being used for diseases caused by MPO, an enzyme associated with chronic inflammatory diseases.